EGFR and neoplasm: Crucially, the results demonstrate the efficient capability of aptamer-conjugated nanoplatforms not only to selectively enter target cells and induce cell death in 2D cell cultures but also uniformly spread into both breast cancer spheroids and organoids and disrupt them through recognition of EGFR+ tumor cells and PDGFRβ+ stromal cells, highlighting the superiority of dual-aptamer-decorated nanoparticles over single-aptamer-conjugated counterparts.